EP0643689B1 - Improved process for the synthesis of (5r)-1,1-dimethylethyl 6-cyano-5-hydroxy-3-oxo-hexanoate - Google Patents
Improved process for the synthesis of (5r)-1,1-dimethylethyl 6-cyano-5-hydroxy-3-oxo-hexanoate Download PDFInfo
- Publication number
- EP0643689B1 EP0643689B1 EP92921435A EP92921435A EP0643689B1 EP 0643689 B1 EP0643689 B1 EP 0643689B1 EP 92921435 A EP92921435 A EP 92921435A EP 92921435 A EP92921435 A EP 92921435A EP 0643689 B1 EP0643689 B1 EP 0643689B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- compound
- formula
- hydroxybutyric acid
- group
- cyanide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/19—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and carboxyl groups, other than cyano groups, bound to the same saturated acyclic carbon skeleton
- C07C255/21—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and carboxyl groups, other than cyano groups, bound to the same saturated acyclic carbon skeleton the carbon skeleton being further substituted by doubly-bound oxygen atoms
Definitions
- the aforementioned compound is useful as an inhibitor of the enzyme 3-hydroxy-3-methylglutaryl-Coenzyme A reductase (HMG-CoA reductase) and is thus useful as a hypolipidemic and hypocholesterolemic agent.
- HMG-CoA reductase 3-hydroxy-3-methylglutaryl-Coenzyme A reductase
- (4R-Cis)-1,1-dimethylethyl 6-(2-aminoethyl)-2,2-dimethyl-1,3-dioxane-4-acetate may be, in turn, prepared from (4R-Cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate which may, in turn, be prepared from (5R)-1,1-dimethylethyl 6-cyano-5-hydroxy-3-oxo-hexanoate.
- the object of the present invention is an improved, short, efficient, and economical process for the preparation of (5R)-1,1-dimethylethyl 6-cyano-5-hydroxy-3-oxo-hexanoate.
- the present method avoids costly starting materials, protection and deprotection of intermediates of the prior method and is amenable to large scale synthesis.
- a first aspect of the present invention is an improved process for the preparation of the compound of Formula I which comprises:
- a second aspect of the present invention is an improved process for the preparation of a compound of Formula II wherein R is alkyl of from one to ten carbon atoms, allyl, or benzyl which comprises: treating a compound of Formula V wherein X is a leaving group and R is as defined above with a compound of Formula IV R 1 -CN wherein R 1 is tetraalkylammonium, silver, copper (I), copper (II), an alkali metal or an alkaline earth metal in a solvent at 0°C to the reflux temperature of the solvent to afford a compound of Formula II.
- alkyl means a straight or branched hydrocarbon radical having from one to ten carbon atoms and includes, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, secondary-butyl, isobutyl, tertiary butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, and n-decyl.
- Aryl means an aromatic radical which is a phenyl group or a phenyl group substituted by one to three substituents selected from the group consisting of alkyl of from one to three carbon atoms, halogen, and nitro.
- Halogen is iodine, bromine, chlorine, and fluorine.
- Alkali metal is a metal in Group IA of the periodic table and includes, for example, lithium, sodium, and potassium.
- Alkaline-earth metal is a metal in Group IIA of the periodic table and includes, for example, calcium, barium, strontium, and magnesium.
- Leaving group is halogen, R 3 -SO 3 - wherein R 3 is alkyl of from one to four carbon atoms or aryl or R 4 / 3 - wherein R 4 is alkyl of from one to four carbon atoms or benzyl.
- the process of the present invention is a new, improved, economical, and commercially feasible method for preparing (5R)-1,1-dimethylethyl 6-cyano-5-hydroxy-3-oxo-hexanoate.
- the process of the present invention is outlined in the following Scheme I:
- a compound of Formula II wherein R is alkyl of from one to ten carbon atoms, allyl, or benzyl is prepared by treating a compound of Formula V wherein X is a leaving group such as, for example, halogen such as chlorine, bromine, iodine, fluorine, and the like, R 3 -SO 3 - wherein R 3 is alkyl of from one to four carbon atoms or aryl such as, for example, para-toluenesulfonyloxy and methanesulfonyloxy or R 4 / 3 - wherein R 4 is alkyl of from one to four carbon atoms or benzyl, and R is as defined above with a compound of Formula IV wherein R 1 is tetraalkylammonium, silver, copper (I), copper (II), an alkali metal or an alkaline earth metal, and a solvent such as, for example, ethanol, dimethylformamide, tetrahydrofuran, water,
- a compound of Formula II is prepared by treating a compound of Formula VI wherein R is as defined above with a compound of Formula IV in a solvent at 0°C to the reflux temperature of the solvent to afford a compound of Formula II.
- the reaction is carried out wherein R is ethyl in a compound of Formula II in ethanol-water at 15°C to 20°C.
- the compound of Formula I is prepared by treating a compound of Formula II with a compound of Formula III wherein R 2 is zinc, magnesium, lithium, sodium, or potassium in an aprotic solvent such as, for example, tetrahydrofuran, hexanes, diethyl ether, tertiary butyl methyl ether, mixtures thereof, for example, tetrahydrofuran-hexanes, tetrahydrofuran-diethyl ether, tetrahydrofuran-tertiary butyl methyl ether, hexanes-diethyl ether, hexanes-tertiary butyl methyl ether, diethyl ether-tertiary butyl methyl ether, at -80°C to 10°C for 1 minute to 4 hours, in the presence of additional compound of Formula III or a base such as, for example, lithium diisopropylamide, and optionally in the presence of added salt such as, for example, zinc
- a compound of Formula III is prepared by treating tertiary butyl acetate with a strong base such as, for example, lithium diisopropylamide.
- a compound of Formula III is prepared from, for example, 2-chloro tertiary-butyl acetate or 2-bromo tertiary butyl acetate by reaction with a zero valent metal such as zinc, magnesium or lithium using conventional methodology.
- a compound of Formula V wherein X is halogen is prepared using conventional methodology from known starting materials.
- a compound of Formula V wherein X is bromo is prepared according to the methodology disclosed by Bock, K., et al, Acta Chemica Scandinavica B37, pages 341-344 (1983). This compound may be prepared by other conventional means.
- a compound of Formula V wherein X is chloro may be prepared using the methodology disclosed by Kitamura, M., et al, Tetrahedron Letters, Volume 29, pages 1555-1556 (1988).
- a compound of Formula V wherein X is iodo is prepared from a compound of Formula V wherein X is chloro using conventional methodology.
- a compound of Formula V wherein X is R 3 -SO 3 - is prepared using conventional methodology from known starting materials.
- a compound of Formula V wherein X is para-toluenesulfonyloxy or methanesulfonyloxy is prepared by reacting (S) 3,4-dihydroxybutanoic acid, ethyl ester which is prepared by the method of Saito, S., et al, Chemistry Letters, pages 1389-1392 (1984) with respectively para-toluenesulfonyl chloride or methanesulfonyl chloride.
- a compound of Formula V wherein X is R 4 / 3 - is prepared from a compound of Formula V wherein X is bromo using the methodology disclosed by Bock, K., et al, Acta Chemica Scandinavica B37, pages 341-344 (1983).
- a compound of Formula VI is prepared from a compound of Formula V using conventional methodology.
- a compound of Formula IV is either known or capable of being prepared by methods known in the art.
- Step A Preparation of (R)-4-Cyano-3-hydroxybutyric acid, ethyl ester
- the lower layer is separated and washed three times with 100 mL of water, then concentrated in vacuo to an oil.
- the crude oil is slurried in 16 mL of ethanol and 20 mL of water and 1.2 g of sodium cyanide is added to the stirred solution.
- the reaction mixture is diluted by the addition of 50 mL of ethyl acetate and 2 g of sodium chloride. The mixture is thoroughly agitated and the layers allowed to separate.
- the lower aqueous layer is rewashed with 50 mL of ethyl acetate.
- the organic layers are combined and concentrated in vacuo.
- the crude product is dissolved in 60 mL of water and the aqueous layer washed with 10 mL of toluene. The aqueous layer is then extracted by adding 10 g of sodium chloride and 100 mL of ethyl acetate, agitating vigorously and separating the top organic layer. The organic layer is concentrated in vacuo and the product is purified by column chromatography on flash silica gel, eluting with 1:1 hexane:ethyl acetate followed by vacuum distillation to afford 1.0 g of the title compound; b.p. 110-125°C @ 0.5 mm Hg.
- Vapor phase chromatography 30 meter DB-5 capillary column 100(2) to 280(15) at 15°C/min. 7.28 minutes retention time, 85.6% area.
- GC/MS m/e 157, 130, 112, 94, 71, 43.
- the reaction mixture is stirred for 30 minutes at -5°C to -30°C, and transferred to 240 L of 0°C 2.8 N aqueous hydrochloric acid solution.
- the aqueous layer is extracted with 50 kg of ethyl acetate, the aqueous layer is separated and reextracted with 36 kg of ethyl acetate, the extracts are combined and concentrated in vacuo to afford crude (5R)-1, 1-dimethylethyl 6-cyano-5-hydroxy-3-oxohexanoate which is not isolated.
- a small sample is purified by column chromatography on flash silica gel eluting with 1:1 hexane:ethyl acetate.
- the reaction is quenched by the addition of 7.5 L (118.5 mol) of acetic acid and concentrated by vacuum distillation to an oil.
- the residue is dissolved with 40 L of methanol, concentrated by vacuum distillation, redissolved with 44 L of methanol and reconcentrated by vacuum distillation to give a brown oil.
- This oil is taken up in 90 L of ethyl acetate and washed with 30 L of deionized water.
- the ethyl acetate solution is concentrated by vacuum distillation to give the title compound, [R-(R*,R*)]-1,1-dimethylethyl 6-cyano-3,5-dihydroxyhexanoate, which is used without further purification.
- Step B Preparation of (4R-Cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate
- a suspension of 100 kg of 4-methyl-3-oxo-N-phenylpentanamide (Example A) in 660 kg of hexanes is treated with agitation under nitrogen with 8 kg of ⁇ -alanine, 47 kg of benzaldehyde, and 13 kg of glacial acetic acid.
- the resulting suspension is heated to reflux with removal of water for 20 hours.
- An additional 396 kg of hexanes and 3 kg of glacial acetic acid is added and reflux continued with water removal for 1 hour.
- the reaction mixture is cooled to 20°C to 25°C, and the product is isolated by filtration.
- the product is purified by slurring in hexanes at 50°C-60°C, cooling, and filtration.
- VPC Vapor Phase Chromatography
- GC/MS Gas Chromatography/Mass Spectrometry
- Step B Preparation of ( ⁇ ) 4-Fluoro- ⁇ -[2-methyl-1-oxopropyl]- ⁇ -oxo-N- ⁇ -diphenylbenzenebutaneamide mixture of [R-(R*,R*)], [R-(R*,S*)] [S-(R*,R*)] and [S-(R*,S*)]isomers
- a solution of 17.5 kg of 3-ethyl-5-(2-hydroxyethyl)-4-methylthiazolium bromide in 300 L of anhydrous ethanol is concentrated by distillation of 275 L of the ethanol.
- 100 kg (340 mol) of 4-methyl-3-oxo-N-phenyl-2-(phenylmethylene)pentamide, 47.5 L (340 mol) of triethylamine, and 40 L (375 mol) of 4-fluorobenzaldehyde are added.
- the resulting solution is stirred and heated at 75°C to 80°C for 23 hours.
- the slurry is dissolved in 600 L of isopropanol at 80°C.
- Step A Preparation of (4R-cis)-1,1-dimethylethyl6-[2[2-(4-fluorophenyl)-5-(1-methylethyl)-3-phenyl-4-[(phenylamino) carbonyl]-1H-pyrrol-1-yl]ethyl]-2,2-dimethyl-1,3-dioxane-4-acetate
- Step B Preparation of (2R-Trans)-5-(4-fluorophenyl)-2-(1-methylethyl)-N,4-diphenyl-1-[2-(tetrahydro-4hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1H-pyrrole-3-carboxamide
- the reaction is stopped by adding 150 mL of water, 90 mL of hexane, and separating the layers.
- the aqueous layer is acidified with dilute hydrochloric acid solution, stirred for 3 hours and extracted with 150 mL of ethyl acetate.
- a drop of concentrated hydrochloric acid is added to the ethyl acetate solution and the solution is allowed to stand 18 hours.
- the solution is concentrated in vacuo and the concentrate is redissolved in 50 mL of ethyl acetate and treated with one drop of concentrated hydrochloric acid.
- the solution is stirred 2 hours, concentrated in vacuo, and dissolved in 3.0 mL of toluene.
- the solution is cooled and poured into 300 mL of tetrahydrofuran and 150 mL of saturated ammonium chloride in water. The layers are separated and the organic layer is added to 15 mL of 10% hydrochloric acid solution and the solution is stirred for 15 hours. To this solution is added sodium hydroxide (3.6 g) and the mixture is stirred for 30 hours. The reaction is stopped by adding 150 mL of water, 90 mL of hexane, and separating the layers. The aqueous layer is acidified with dilute hydrochloric acid solution, stirred for 3 hours and extracted with 150 mL of ethyl acetate.
- a drop of concentrated hydrochloric acid is added to the ethyl acetate solution and the solution is allowed to stand 18 hours.
- the solution is concentrated in vacuo and the concentrate is redissolved in 50 mL of ethyl acetate and treated with one drop of concentrated hydrochloric acid.
- the solution is stirred 2 hours, concentrated in vacuo, and dissolved in 3.0 mL of toluene.
- a three-necked, 12-L round-bottom flask equipped with a mechanical stirrer, a thermometer, and set up for distillation is charged with 2.6 L of toluene, 1.73 kg (12 mol) of methyl 4-methyl-3-oxopentanoate and 72 g (1.18 mol) of ethylenediamine.
- the mixture is heated to 80°C and charged with 0.49 kg of aniline.
- the mixture is brought to reflux and distillation started. After 40 minutes a further 0.245 kg of aniline is charged and at 40-minute intervals a further two portions of aniline (0.245 and 0.25 kg) are charged. Distillation is continued for a further one to five hours until a total of 985 mL of solvent is removed.
- the solution is stirred at room temperature for 16 hours and a further 550 mL of solvent is removed by vacuum distillation (using approximately 85 mm Hg).
- the mixture is cooled and 2 L of water is charged to provide an oil.
- the mixture is warmed to 40°C and a further 1.0 L of water is charged.
- Seven hundred milliliters of toluene-water mixture is removed by vacuum distillation (approximately 20 mm Hg). Two liters of water is charged and the mixture is allowed to stand for 10 days.
- the product is isolated by filtration and washed with three portions of hexane.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Catalysts (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/775,162 US5155251A (en) | 1991-10-11 | 1991-10-11 | Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate |
US775162 | 1991-10-11 | ||
PCT/US1992/008441 WO1993007115A1 (en) | 1991-10-11 | 1992-10-05 | Improved process for the synthesis of (5r)-1,1-dimethylethyl 6-cyano-5-hydroxy-3-oxo-hexanoate |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0643689A1 EP0643689A1 (en) | 1995-03-22 |
EP0643689B1 true EP0643689B1 (en) | 1998-12-30 |
Family
ID=25103514
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP92921435A Expired - Lifetime EP0643689B1 (en) | 1991-10-11 | 1992-10-05 | Improved process for the synthesis of (5r)-1,1-dimethylethyl 6-cyano-5-hydroxy-3-oxo-hexanoate |
Country Status (16)
Country | Link |
---|---|
US (1) | US5155251A (pt) |
EP (1) | EP0643689B1 (pt) |
JP (2) | JP3241723B2 (pt) |
AT (1) | ATE175190T1 (pt) |
AU (1) | AU667320B2 (pt) |
CA (1) | CA2116973C (pt) |
DE (1) | DE69228073T2 (pt) |
DK (1) | DK0643689T3 (pt) |
ES (1) | ES2129457T3 (pt) |
FI (1) | FI941632A (pt) |
MX (1) | MX9205824A (pt) |
NO (1) | NO300208B1 (pt) |
PT (1) | PT100943B (pt) |
SG (1) | SG46599A1 (pt) |
WO (1) | WO1993007115A1 (pt) |
ZA (1) | ZA927793B (pt) |
Families Citing this family (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5245047A (en) * | 1988-02-22 | 1993-09-14 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
JP3171931B2 (ja) * | 1992-06-02 | 2001-06-04 | 高砂香料工業株式会社 | (R)−(−)−4−シアノ−3−ヒドロキシ酪酸t−ブチルエステル及びその製造方法 |
US5298627A (en) * | 1993-03-03 | 1994-03-29 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
GB9512837D0 (en) * | 1995-06-23 | 1995-08-23 | Zeneca Ltd | reduction of ketone groups |
HRP960312B1 (en) | 1995-07-17 | 2001-10-31 | Warner Lambert Co | NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1) |
US6087511A (en) * | 1996-07-16 | 2000-07-11 | Warner-Lambert Company | Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1) |
US5908953A (en) * | 1996-12-18 | 1999-06-01 | Mitsubishi Chemical Corporation | Method for producing (R)-4-cyano-3-hydroxybutyric acid lower alkyl ester |
JPH11171850A (ja) * | 1997-12-12 | 1999-06-29 | Kanegafuchi Chem Ind Co Ltd | 酪酸エステル誘導体の製造方法 |
PL193678B1 (pl) | 1997-12-19 | 2007-03-30 | Warner Lambert Exp Ltd | Sposób wytwarzania cis-1,3-diolu, synergiczna kombinacja oraz zastosowanie synergicznej kombinacji |
ES2207202T3 (es) * | 1998-04-30 | 2004-05-16 | Kaneka Corporation | Procedimiento para producir derivados de acido 6-cianometil-1, 3-dioxano-4-acetico. |
EP1024139B1 (en) * | 1998-08-05 | 2004-05-12 | Kaneka Corporation | Process for the preparation of optically active 2-(6-(hydroxymethyl)-1,3-dioxan-4-yl) acetic acid derivatives |
KR100313668B1 (ko) * | 1999-02-03 | 2001-11-26 | 박영구 | (r)-4-시아노-3-히드록시부티르산 에스테르의 제조방법 |
HU227840B1 (en) * | 1999-05-06 | 2012-05-02 | Egis Gyogyszergyar Nyilvanosan M Kod Ruszvunytarsasag | Intermediates of atorvastatin synthesis and process for producing them |
ES2219345T3 (es) * | 1999-06-04 | 2004-12-01 | Kaneka Corporation | Procedimiento para la preparacion de derivados del acido 5-hidroxi-3-oxopentanoico. |
US20040063969A1 (en) * | 1999-10-18 | 2004-04-01 | Egis Gyogyszergyar Rt. | Process for the preparation of amorphous atorvastatin calcium |
EP1584616A1 (en) | 1999-12-17 | 2005-10-12 | Pfizer Science and Technology Ireland Limited | Industrial process for the production of crystalline atorvastatin trihydrate hemi calcium salt |
ES2258030T3 (es) * | 1999-12-17 | 2006-08-16 | Pfizer Science And Technology Ireland Limited | Procedimiento para producir atorvastatina calcio cristalina. |
CN100368386C (zh) * | 2000-05-31 | 2008-02-13 | 中国医学科学院药物研究所 | (±)对氟-2-(2-甲基-丙酰基)-4-氧-n,3-二苯基-苯丁酰胺的合成方法以及其中的中间体 |
CN101250133B (zh) * | 2000-05-31 | 2010-06-09 | 中国医学科学院药物研究所 | (±)对氟-2-(2-甲基-丙酰基)-4-氧-n,3-二苯基-苯丁酰胺的合成方法以及其中的中间体 |
EP1728785A1 (en) | 2001-01-09 | 2006-12-06 | Warner-Lambert Company LLC | 7-[(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-phenylcarbamoyl-pyrrol-1-yl]-heptanoic acid ester 3,5-dioxo-acetal |
US6476235B2 (en) * | 2001-01-09 | 2002-11-05 | Warner-Lambert Company | Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide |
WO2002057229A1 (en) * | 2001-01-19 | 2002-07-25 | Biocon India Limited | FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN) |
SI20814A (sl) | 2001-01-23 | 2002-08-31 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Priprava amorfnega atorvastatina |
SI20848A (sl) | 2001-03-14 | 2002-10-31 | Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. | Farmacevtska formulacija, ki vsebuje atorvastatin kalcij |
CN1524073A (zh) | 2001-06-29 | 2004-08-25 | ����-�����ع�˾ | ′R-(R*,R*)-2-(4-氟苯基)-β,δ-二羟基-5-(1-甲基乙基)-3-苯基-4-(苯基氨基)羰基-1H-吡咯-1-庚酸钙盐(2∶1)(阿托伐他汀) |
EP1406860A1 (en) * | 2001-07-06 | 2004-04-14 | Teva Pharmaceutical Industries Limited | Process for the preparation of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives via 6-cyano syn 3,5-dihydroxy hexanoic acid derivatives |
CA2453211A1 (en) | 2001-07-06 | 2003-01-16 | Teva Pharmaceutical Industries Ltd. | Process for the preparation of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives, intermediates thereof and methods for their preparation |
HUP0401145A3 (en) | 2001-07-06 | 2008-08-28 | Ciba Sc Holding Ag | Process for the preparation of intermediates useful in the synthesis of statin derivatives especially 7-amino 3,5-dihydroxy heptanoic acid derivatives, and intermediates thereof |
JP4765217B2 (ja) * | 2001-07-30 | 2011-09-07 | 住友化学株式会社 | (r)−4−シアノ−3−ヒドロキシブタン酸エステルの製造法 |
JP2005500351A (ja) | 2001-07-30 | 2005-01-06 | ドクター・レディーズ・ラボラトリーズ・リミテッド | 結晶形態viおよびviiのアトルバスタチンカルシウム |
PE20030324A1 (es) * | 2001-07-31 | 2003-04-03 | Warner Lambert Co | Composiciones farmaceuticas de amlodipina y atorvastatina |
AU2001284385A1 (en) * | 2001-08-31 | 2003-03-10 | Morepen Laboratories Ltd. | An improved process for the preparation of amorphous atorvastatin calcium salt (2:1) |
UA77990C2 (en) * | 2001-12-12 | 2007-02-15 | Crystalline calcium salt of (2:1) [r-(r*,r*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid | |
KR100849880B1 (ko) * | 2001-12-20 | 2008-08-01 | 주식회사 중외제약 | 광학활성 2-[6-(치환된 알킬)-1,3-디옥산-4-일]아세트산유도체의 신규 제조 방법 |
CZ296967B6 (cs) | 2002-02-01 | 2006-08-16 | Zentiva, A.S. | Zpusob výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) |
DE10212492B4 (de) * | 2002-03-21 | 2012-02-02 | Daimler Ag | Kolbenpumpe |
PL375415A1 (en) * | 2002-08-06 | 2005-11-28 | Warner-Lambert Company Llc | Process for preparing 5-(4-fluorophenyl)-1-[2-((2r,4r)-4-hydroxy -6-oxo-tetrahydro-pyran-2-yl)ethyl]-2-isopropyl-4-phenyl-1h-pyrrole-3-carboxylic acid phenylamide |
CA2493941A1 (en) * | 2002-08-09 | 2004-02-19 | Codexis, Inc. | Enzymatic processes for the production of 4-substituted 3-hydroxybutyric acid derivatives |
JP2006503024A (ja) * | 2002-09-03 | 2006-01-26 | モレペン、ラボラトリーズ、リミテッド | Vi型アトルバスタチンカルシウムまたはその水和物 |
HRP20020885B1 (en) * | 2002-11-11 | 2007-05-31 | GlaxoSmithKline istra�iva�ki centar Zagreb d.o.o. | SUBSTITUTED 9a-N-{N'-[4-(SULFONYL)PHENYLCARBAMOYL]}DERIVATIVES 9-DEOXO-9-DIHYDRO-9a-AZA-9a-HOMOERITHROMYCIN A AND 5-O-DESOZAMINYL-9-DEOXO-9-DIHYDRO-9a-AZA-9a-HOMOERITHRONOLIDE A |
CN1774421A (zh) * | 2003-04-14 | 2006-05-17 | 沃尼尔·朗伯有限责任公司 | 制备5-(4-氟苯基)-1-[2-((2r,4r)-4-羟基-6-氧代-四氢-吡喃-2-基)乙基]-2-异丙基-4-苯基-1h-吡咯-3-羧酸苯基酰胺的方法 |
US20050182125A1 (en) * | 2003-05-16 | 2005-08-18 | Ambit Biosciences Corporation | Pyrrole compounds and uses thereof |
US20040248972A1 (en) * | 2003-05-16 | 2004-12-09 | Ambit Biosciences Corporation | Compounds and uses thereof |
WO2004103960A2 (en) * | 2003-05-16 | 2004-12-02 | Ambit Biosciences Corporation | Compounds and uses thereof |
US7790197B2 (en) * | 2003-06-09 | 2010-09-07 | Warner-Lambert Company Llc | Pharmaceutical compositions of atorvastatin |
US20050271717A1 (en) | 2003-06-12 | 2005-12-08 | Alfred Berchielli | Pharmaceutical compositions of atorvastatin |
US7655692B2 (en) * | 2003-06-12 | 2010-02-02 | Pfizer Inc. | Process for forming amorphous atorvastatin |
US20040253305A1 (en) * | 2003-06-12 | 2004-12-16 | Luner Paul E. | Pharmaceutical compositions of atorvastatin |
CN1852894A (zh) * | 2003-09-17 | 2006-10-25 | 沃尼尔·朗伯有限责任公司 | [R-(R*, R*)]-2-(4-氟苯基) -β,δ-二羟基-5-(1-甲基乙基) -3-苯基-4-[(苯基氨基)羰基] -1 H-吡咯-1-庚酸的结晶形式 |
WO2005026107A1 (en) * | 2003-09-18 | 2005-03-24 | Biocon Limited | Novel process for the preparation of tert-butyl 6-cyano-5-hydroxy-3-oxohexanoate |
EP1711489B1 (en) * | 2003-12-29 | 2012-12-26 | LEK Pharmaceuticals d.d. | Process for preparing amorphous (4r-cis)-6-[2-[3-phenyl-4-(phenylcarbamoyl)-2-(4-fluorophenyl)-5-(1-methyl)-pyrrol-1-yl]-2,2-dimethyl-[1,3]-dioxane-4-yl-acetic acid |
CA2456430A1 (en) * | 2004-01-28 | 2005-07-28 | Brantford Chemicals Inc. | Improved process for the preparation of amorphous atorvastatin calcium |
EP1727795B1 (en) | 2004-03-17 | 2012-02-15 | Ranbaxy Laboratories Limited | Process for the production of atorvastatin calcium in amorphous form |
BRPI0509923A (pt) * | 2004-04-16 | 2007-09-18 | Pfizer Prod Inc | processo para formação de cálcio de atorvastatina amorfa |
CA2564030C (en) | 2004-05-05 | 2010-06-08 | Pfizer Products Inc. | Salt forms of [r-(r*, r*)]-2-(4-fluorophenyl)-.beta., .delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid |
RU2412191C2 (ru) * | 2004-07-16 | 2011-02-20 | Лек Фармасьютиклз Д.Д. | Продукты окислительной деструкции кальций аторвастатина |
JP2008506764A (ja) | 2004-07-20 | 2008-03-06 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | [R−(R*,R*)]−2−(4−フルオロフェニル)−β、δ−ジヒドロキシ−5−(1−メチルエチル)−3−フェニル−4−[(フェニルアミノ)カルボニル]−1H−ピロール−1−ヘプタン酸カルシウム塩(2:1)の新規形態 |
JP2008510798A (ja) * | 2004-08-27 | 2008-04-10 | バイオコン・リミテッド | 非晶質アトルバスタチンカルシウムのための方法 |
EP1807055A1 (en) | 2004-10-28 | 2007-07-18 | Warner-Lambert Company LLC | Process for forming amorphous atorvastatin |
EP1814541A4 (en) * | 2004-11-22 | 2009-10-28 | Dexcel Pharma Technologies Ltd | STABLE ATORVASTATIN FORMULATIONS |
CA2589537A1 (en) * | 2004-12-02 | 2006-06-08 | Stephen Craig Dyar | Pharmaceutical compositions of amorphous atorvastatin and process for preparing same |
US20090221839A1 (en) * | 2005-09-09 | 2009-09-03 | Pfizer Inc. | Preparation of an Atorvastatin Intermediate |
US20090221852A1 (en) * | 2005-09-09 | 2009-09-03 | Pfizer Inc. | Preparation of an Atorvastatin Intermediate |
US20090216029A1 (en) * | 2005-09-16 | 2009-08-27 | Yatendra Kumar | Process for the production of atorvastatin calcium in amorphous form |
CA2547216A1 (en) | 2005-09-21 | 2007-03-21 | Renuka D. Reddy | Process for annealing amorphous atorvastatin |
DE602006014193D1 (de) | 2005-11-21 | 2010-06-17 | Warner Lambert Co | Neue formen von är-(r*,r*)ü-2-(4-fluorphenyl)-b,d-dihydroxy-5-(1-methylethyl)-3-phenyl-4-ä(phenylamino)carbonylü-1h-pyrrol-1-heptansäure-magnesium |
EP1810667A1 (en) | 2006-01-20 | 2007-07-25 | KRKA, tovarna zdravil, d.d., Novo mesto | Pharmaceutical composition comprising amorphous atorvastatin |
CN101528917B (zh) | 2006-10-02 | 2015-07-29 | 科德克希思公司 | 用于制备立体异构纯的他汀类及其合成中间体的组合物和方法 |
WO2008053312A2 (en) * | 2006-11-02 | 2008-05-08 | Cadila Pharmaceuticals Limited | Process for preparing amorphous atorvastatin hemi calcium salt and its intermediate |
WO2008059366A2 (en) * | 2006-11-17 | 2008-05-22 | Pfizer Products Inc. | Process for the preparation of cis-1, 3-diols from the corresponding beta-hydroxy ketones employing microbial ketone reductases |
US7834195B2 (en) * | 2007-01-24 | 2010-11-16 | Apotex Pharmachem Inc. | Atorvastatin calcium propylene glycol solvates |
US20110142883A1 (en) * | 2007-07-20 | 2011-06-16 | Actavis Group Ptc Ehf | Amorphous Coprecipitates of Atorvastatin Pharmaceutically Acceptable Salts |
EP2185713B1 (en) | 2007-08-03 | 2014-09-10 | Pfizer Products Inc. | Process for preparing chiral compounds |
EP2075246A1 (en) | 2007-12-27 | 2009-07-01 | M. J. Institute of Research | A process for preparation of amorphous form of atorvastatin hemi-calcium salt |
US8115015B2 (en) * | 2009-01-26 | 2012-02-14 | Cadila Healthcare Limited | Process for the preparation of amorphous atorvastatin calcium |
GB2474687A (en) | 2009-10-23 | 2011-04-27 | Phoenix Chemicals Ltd | A continuous process for the production of (R)-6-cyano-5-hydroxy-3-oxo-hexanoic acid tert-butyl ester (and derivatives) |
KR20120011249A (ko) | 2010-07-28 | 2012-02-07 | 주식회사 경보제약 | 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법 |
EP2614057B1 (en) * | 2010-09-09 | 2015-10-21 | DSM Sinochem Pharmaceuticals Netherlands B.V. | Salts of 7-amino-3,5-dihydroxyheptanoic acid esters |
US20140335179A1 (en) | 2011-07-01 | 2014-11-13 | Dsm Sinochem Pharmaceuticals Netherlands B.V. | Micronized crystals of atorvastatin hemicalcium |
CN102766072B (zh) * | 2012-08-07 | 2013-12-25 | 浙江宏元药业有限公司 | 一种制备阿托伐他汀钙手性侧链的方法 |
CN103145584B (zh) * | 2013-03-05 | 2015-08-26 | 复旦大学 | 一种合成(3r,5r)-3,5-二羟基-6-氰基己酸酯的方法 |
CN106397241A (zh) * | 2016-08-23 | 2017-02-15 | 杨锋 | 一种4‑甲基‑3‑氧代‑n‑苯基戊酰胺的绿色环保后处理方法 |
CN108033899B (zh) * | 2017-12-06 | 2020-04-10 | 浙江科技学院 | 一种(r)-6-氰基-5-羟基-3-羰基己酸叔丁酯的制备方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4647576A (en) * | 1984-09-24 | 1987-03-03 | Warner-Lambert Company | Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis |
US4611067A (en) * | 1985-01-31 | 1986-09-09 | Merck & Co., Inc. | Process for the preparation of HMG-CoA reductase inhibitors and intermediate compounds employed therein |
US4681893A (en) * | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
DE3741509A1 (de) * | 1987-12-08 | 1989-06-22 | Hoechst Ag | Verfahren zur herstellung optisch aktiver 3-desmethylmevalonsaeurederivate sowie zwischenprodukte |
US5003080A (en) * | 1988-02-22 | 1991-03-26 | Warner-Lambert Company | Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis |
-
1991
- 1991-10-11 US US07/775,162 patent/US5155251A/en not_active Expired - Lifetime
-
1992
- 1992-10-05 JP JP50710093A patent/JP3241723B2/ja not_active Expired - Fee Related
- 1992-10-05 WO PCT/US1992/008441 patent/WO1993007115A1/en active IP Right Grant
- 1992-10-05 AT AT92921435T patent/ATE175190T1/de not_active IP Right Cessation
- 1992-10-05 AU AU27641/92A patent/AU667320B2/en not_active Ceased
- 1992-10-05 EP EP92921435A patent/EP0643689B1/en not_active Expired - Lifetime
- 1992-10-05 DE DE69228073T patent/DE69228073T2/de not_active Expired - Fee Related
- 1992-10-05 ES ES92921435T patent/ES2129457T3/es not_active Expired - Lifetime
- 1992-10-05 CA CA002116973A patent/CA2116973C/en not_active Expired - Fee Related
- 1992-10-05 SG SG1996006497A patent/SG46599A1/en unknown
- 1992-10-05 DK DK92921435T patent/DK0643689T3/da active
- 1992-10-09 MX MX9205824A patent/MX9205824A/es not_active IP Right Cessation
- 1992-10-09 PT PT100943A patent/PT100943B/pt not_active IP Right Cessation
- 1992-10-09 ZA ZA927793A patent/ZA927793B/xx unknown
-
1994
- 1994-04-08 NO NO941280A patent/NO300208B1/no not_active IP Right Cessation
- 1994-04-08 FI FI941632A patent/FI941632A/fi not_active Application Discontinuation
-
2001
- 2001-06-04 JP JP2001167726A patent/JP3429500B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
DK0643689T3 (da) | 1999-08-30 |
CA2116973A1 (en) | 1993-04-15 |
NO941280D0 (no) | 1994-04-08 |
JP3429500B2 (ja) | 2003-07-22 |
AU2764192A (en) | 1993-05-03 |
ES2129457T3 (es) | 1999-06-16 |
ZA927793B (en) | 1994-04-11 |
DE69228073T2 (de) | 1999-06-10 |
FI941632A0 (fi) | 1994-04-08 |
NO941280L (no) | 1994-04-08 |
WO1993007115A1 (en) | 1993-04-15 |
CA2116973C (en) | 2004-09-21 |
DE69228073D1 (de) | 1999-02-11 |
MX9205824A (es) | 1993-04-01 |
ATE175190T1 (de) | 1999-01-15 |
JP2002030060A (ja) | 2002-01-29 |
US5155251A (en) | 1992-10-13 |
SG46599A1 (en) | 1998-02-20 |
PT100943B (pt) | 1999-07-30 |
JP3241723B2 (ja) | 2001-12-25 |
PT100943A (pt) | 1993-10-29 |
FI941632A (fi) | 1994-04-08 |
EP0643689A1 (en) | 1995-03-22 |
AU667320B2 (en) | 1996-03-21 |
JPH07500105A (ja) | 1995-01-05 |
NO300208B1 (no) | 1997-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0643689B1 (en) | Improved process for the synthesis of (5r)-1,1-dimethylethyl 6-cyano-5-hydroxy-3-oxo-hexanoate | |
US5103024A (en) | Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate | |
EP0915866B1 (en) | Improved process for the synthesis of protected esters of (s)-3,4-dihydroxybutyric acid | |
EP0330172B1 (en) | Improved process for trans-6-[2-(substituted-pyrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis | |
US5248793A (en) | Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate | |
US5280126A (en) | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis | |
US5149837A (en) | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis | |
US5097045A (en) | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis | |
US5216174A (en) | Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis | |
CZ285554B6 (cs) | Způsob výroby trans-6-[2-(substituovaný pyrrol-1-yl)alkyl]-pyran-2-onu | |
AU3349689A (en) | Improved process for trans-6-(2-(substituted-pyrrol-1-yl) alkyl)pyran-2-one inhibitors of cholesterol synthesis | |
NO177423B (no) | Forbedret fremgangsmåte for fremstilling av trans-6-[2-(substituert-pyrrol-yl)alkylÅpyran-2-on-inhibitorer for kolesterolsyntese |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19940402 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL SE |
|
17Q | First examination report despatched |
Effective date: 19960605 |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL SE |
|
REF | Corresponds to: |
Ref document number: 175190 Country of ref document: AT Date of ref document: 19990115 Kind code of ref document: T |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REF | Corresponds to: |
Ref document number: 69228073 Country of ref document: DE Date of ref document: 19990211 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: SCHMAUDER & PARTNER AG PATENTANWALTSBUERO |
|
ET | Fr: translation filed | ||
ITF | It: translation for a ep patent filed |
Owner name: ORGANIZZAZIONE D'AGOSTINI |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2129457 Country of ref document: ES Kind code of ref document: T3 |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed | ||
REG | Reference to a national code |
Ref country code: GB Ref legal event code: IF02 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DK Payment date: 20080916 Year of fee payment: 17 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20080915 Year of fee payment: 17 Ref country code: MC Payment date: 20080923 Year of fee payment: 17 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20080915 Year of fee payment: 17 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: LU Payment date: 20081021 Year of fee payment: 17 Ref country code: IE Payment date: 20081016 Year of fee payment: 17 Ref country code: DE Payment date: 20081031 Year of fee payment: 17 Ref country code: CH Payment date: 20081028 Year of fee payment: 17 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20081023 Year of fee payment: 17 Ref country code: AT Payment date: 20080915 Year of fee payment: 17 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20081007 Year of fee payment: 17 Ref country code: BE Payment date: 20081031 Year of fee payment: 17 Ref country code: IT Payment date: 20081017 Year of fee payment: 17 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20081006 Year of fee payment: 17 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GR Payment date: 20081014 Year of fee payment: 17 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PCAR Free format text: SCHMAUDER & PARTNER AG PATENT- UND MARKENANWAELTE VSP;ZWAENGIWEG 7;8038 ZUERICH (CH) |
|
BERE | Be: lapsed |
Owner name: *WARNER-LAMBERT CY Effective date: 20091031 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: V1 Effective date: 20100501 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20091031 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
EUG | Se: european patent has lapsed | ||
REG | Reference to a national code |
Ref country code: DK Ref legal event code: EBP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20100630 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100501 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20091102 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100501 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20091005 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20091031 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20091005 Ref country code: GR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100504 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20091031 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20091031 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20091005 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20091031 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20110302 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20091005 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20091005 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20091006 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20110301 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20091006 |